English   español  
Por favor, use este identificador para citar o enlazar a este item: http://hdl.handle.net/10261/113711
Compartir / Impacto:
Estadísticas
Add this article to your Mendeley library MendeleyBASE
Ver citas en Google académico
Visualizar otros formatos: MARC | Dublin Core | RDF | ORE | MODS | METS | DIDL
Exportar otros formatos: Exportar EndNote (RIS)Exportar EndNote (RIS)Exportar EndNote (RIS)
Título

Maternal antiasthma simplified herbal medicine intervention therapy prevents airway inflammation and modulates pulmonary innate immune responses in young offspring mice

Autor López-Expósito, Iván ; Srivastava, K.; Birmingham, Neil; Castillo, Alexandra; Miller, Rachel L.; Li, Xiu-Min
Fecha de publicación 2015
EditorElsevier
Citación Annals of Allergy, Asthma and Immunology 114(1): 43-51.e1 (2015)
Resumen[Background]: Maternal asthma is a risk factor for asthma in offspring; however, transmission of the risk for allergic asthma without direct offspring sensitization has not been explored. [Objective]: To determine whether offspring from mothers with ovalbumin (OVA)-sensitized asthma would develop airway disease at first-ever exposure to OVA and whether preconception maternal treatment with the Antiasthma Simplified Herbal Medicine Intervention (ASHMI) or dexamethasone (DEX) could modify this risk in offspring [Methods]: Female BALB/c mice (F0) with OVA-induced asthma were generated using established protocols. Mice with asthma were treated with ASHMI, DEX, or water for 6 to 7 weeks. Naive mice served as controls. Subsequently, mice were mated. Twelve-day-old F1 offspring received 3 consecutive intranasal low- or high-dose OVA exposures without sensitization. Forty-eight hours later, airway inflammation, mucus hypersecretion, serum antibodies, and cytokines were evaluated. [Results]: Offspring from OVA-sensitized mothers, but not naive mothers, showed eosinophilic and neutrophilic airway inflammation, and mucus hyperplasia after OVA exposure and he presence of OVA-specific IgG1 and IgG2a. Offspring of ASHMI- and DEX-treated mothers showed decreased airway inflammation and mucus hypersecretion after low-dose OVA (P <.05-.001 for the 2 comparisons vs offspring of OVA/Sham mothers). Offspring of ASHMI-treated, but not DEX-treated, mothers were protected after the high-dose OVA challenge (P <.05-.01 vs offspring OVA/Sham). Maternal ASHMI therapy was associated with increased IgG2a (P <.01 vs offspring of OVA/Sham mothers) and decreased bronchoalveolar lavage fluid CXCL-1 and eotaxin-1 levels (P <.01 and P <.05, respectively, vs offspring of OVA/Sham mothers). [Conclusion]: Offspring of mothers with OVA-induced asthma developed airway inflammation and mucus to first-ever OVA exposure without prior sensitization. Maternal therapy with ASHMI was superior to DEX in decreasing offspring susceptibility to airway disease and could be a strategy to lower asthma prevalence.
Versión del editorhttp://dx.doi.org/10.1016/j.anai.2014.10.018
URI http://hdl.handle.net/10261/113711
Identificadoresdoi: 10.1016/j.anai.2014.10.018
issn: 1081-1206
e-issn: 1534-4436
Aparece en las colecciones: (CIAL) Artículos
Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
Maternal ASHMI.pdf6,92 MBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro completo
 


NOTA: Los ítems de Digital.CSIC están protegidos por copyright, con todos los derechos reservados, a menos que se indique lo contrario.